Article
Oncology
Zheng Li, Yaming Li, Xiaolong Wang, Qifeng Yang
Summary: The study identified PPP2R2B as a strong tumor suppressor in TNBC, with downregulated expression in TNBC tissues compared to normal breast tissues. Low PPP2R2B expression was associated with shorter survival time and could play a key role in breast cancer initiation and progression. PPP2R2B was also found to be related to specific immune cells and immune inhibitor genes.
CANCER CELL INTERNATIONAL
(2021)
Article
Food Science & Technology
Hsin-Ling Yang, Sheng-Teng Huang, Zi-He Lyu, Asif Ali Bhat, Chithravel Vadivalagan, Yu-Lyu Yeh, You-Cheng Hseu
Summary: Coenzyme Q0 (CoQ0) from Antrodia camphorata exhibits therapeutic benefits in cancer treatment by activating apoptotic and autophagic cell death pathways.
JOURNAL OF FUNCTIONAL FOODS
(2023)
Article
Immunology
Huifang Liu, Jing Wu, Xiaoyu Xu, Han Wang, Changhua Zhang, Songcheng Yin, Yulong He
Summary: The study revealed that the infiltrated levels of TIGIT(+)CD20(+) B cells around tumors in gastric cancer patients were associated with clinical outcomes and could potentially impact the exhaustion of CD8(+) T cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Huihui Li, Li Wang, Wei Zhang, Youting Dong, Yefeng Cai, Xiaoli Huang, Xubin Dong
Summary: This study investigates the functional role of PKMYT1 in breast cancer using bioinformatics methods, clinical samples, and experiments. The results show that PKMYT1 expression is higher in breast cancer tissues, particularly in advanced patients. PKMYT1 expression is associated with prognosis and is closely related to oncogenic or tumor suppressor gene variants. The study also reveals that PKMYT1 expression is upregulated in triple-negative breast cancer and is linked to immune cell infiltration in the tumor microenvironment. In vitro experiments demonstrate that inhibiting PKMYT1 expression inhibits proliferation, migration, and invasion of triple-negative breast cancer cells and induces apoptosis. Therefore, PKMYT1 may serve as a biomarker for prognosis and a therapeutic target for triple-negative breast cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Marine Lemesle, Marine Geoffroy, Fabien Alpy, Catherine-Laure Tomasetto, Sandra Kuntz, Isabelle Grillier-Vuissoz
Summary: This study investigated the role of CLDN1 in triple-negative breast cancer (TNBC) and found that CLDN1 can increase the sensitivity of TNBC cells to chemotherapy drugs. The findings support the use of CLDN1 as a predictive marker for chemotherapy response in TNBC.
Article
Genetics & Heredity
Peng Zhang, Qian Yang
Summary: SHMT2 is significantly overexpressed in BLCA tissues and cells, high SHMT2 expression predicts poor OS and is associated with higher tumor grade and older age in BLCA patients. SHMT2 regulates BLCA cell growth by modulating STAT3 signaling.
FRONTIERS IN GENETICS
(2021)
Article
Biochemistry & Molecular Biology
Dominikay Kazmierczak, Karol Jopek, Karolina Sterzynska, Michal Nowicki, Marcin Rucinski, Radoslaw Januchowski
Summary: This study aimed to detect changes in miRNA expression levels in two cisplatin and two paclitaxel-resistant variants of the A2780 ovarian cancer cell line, and to identify miRNAs responsible for the regulation of drug-resistance genes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
William A. Blessing, Christopher S. Digesu, Rong Liu, David A. Mahvi, Aya Tal-mason, Anil Kumar, Krista J. Hachey, Aaron H. Colby, Jenny T. Korunes-Miller, Natalie Agar, Michael S. Regan, Angela Shih, Chandrajit P. Raut, Mark W. Grinstaff, Yolonda L. Colson
Summary: The risk of locoregional recurrence after sarcoma resection is high. Intraoperative implantation of PTX-eluting films can provide sustained supratherapeutic concentrations of PTX, leading to the reduction of recurrence by irreversibly arresting cell cycle and inducing apoptosis.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Cell Biology
Feng Xiao, Zhenli Long, Yun Guo, Hong Zhu, Zhe Zhang, Yao Xiao, Guowen Hu, Qing Yang, Kai Huang, Hua Guo
Summary: Objective: MAGOH plays a pivotal role in various tumors, but its specific contribution in lower-grade glioma (LGG) is still unknown. Methods: Pan-cancer analysis was conducted to investigate the expression characteristics and prognostic significance of MAGOH in multiple tumors. Results: Increased MAGOH expression was associated with adverse prognosis in LGG patients and correlated with immune-related markers, immune cell infiltration, gene mutations, and responses to chemotherapy. In vitro studies confirmed the essential role of MAGOH in cell proliferation in LGG.
Article
Genetics & Heredity
Janani Ramesh, Rejani Chalikkaran Thilakan, Raja Mohan Gopalakrishnan, Singaravel Vijayapoopathi, Arianna Dorschel, Bhuvarahamurthy Venugopal
Summary: The study aimed to determine the potential of GRg5 as a chemosensitizer in PTX-resistant human cervical adeno-carcinoma cell lines (HeLa cells). The study found that GRg5 can enhance the cytotoxic effect of PTX in PTX-resistant HeLa cells by promoting the expression of Bax and activating caspase-9/-3, leading to apoptosis. Moreover, the study supports GRg5 as an inhibitor of Akt and NF-kappa B, which enhances the susceptibility of cervical cancer cells to PTX chemotherapy.
Article
Oncology
Thierry Voisin, Pascal Nicole, Valerie Gratio, Anais Chassac, Dounia Mansour, Vinciane Rebours, Anne Couvelard, Alain Couvineau
Summary: Orexin-A can effectively inhibit the growth of pancreatic cancer cells and significantly reduce tumor volume in preclinical models. Combination therapy with Orexin-A plus gemcitabine or Orexin-A plus Nab-paclitaxel shows additive effects in inhibiting cancer cell growth and tumor development.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Selim Comakli, Selcuk Ozdemir, Meryem Guloglu
Summary: This study evaluated the protective effect of chrysin against paclitaxel-induced hepatorenal toxicity in rats and found that chrysin can reduce oxidative DNA damage, exert anti-apoptotic and anti-inflammatory properties, and mitigate the toxic effects of paclitaxel-induced hepatorenal toxicity.
Article
Oncology
Haruhiko Yamazaki, Kiminori Sugino, Ryohei Katoh, Kenichi Matsuzu, Chie Masaki, Junko Akaishi, Kiyomi Yamada Hames, Chisato Tomoda, Akifumi Suzuki, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Yasushi Rino, Koichi Ito
Summary: This study investigated the outcomes and prognostic factors in anaplastic thyroid carcinoma (ATC) patients treated with paclitaxel as neoadjuvant therapy. The results showed that prognostic index (PI) >= 2, response to paclitaxel, resection, and radiotherapy were independent prognostic factors for overall survival (OS) in ATC patients. There were no significant predictive factors for response to paclitaxel in baseline characteristics.
Article
Pharmacology & Pharmacy
Guanyu Yu, Mengnan Xu, Leqi Zhou, Kuo Zheng, Xiaoming Zhu, Jinke Sui, Cheng Xin, Wenjun Chang, Wei Zhang, Fuao Cao
Summary: This study investigated the expression of phosphorylated Focal adhesion kinase (p-FAK) in colorectal cancer (CRC) and its association with prognosis. The results showed that high p-FAK expression was associated with poor prognosis and poor chemotherapeutic response in CRC. Therefore, the expression level of p-FAK can serve as an independent prognostic biomarker for CRC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Yuchao Fei, Yifan Cao, Yun Gu, Hanji Fang, Yifan Chen, Jieti Wang, Xin Liu, Kunpeng Lv, Xudong He, Chao Lin, Hao Liu, He Li, Hongyong He, Ruochen Li, Heng Zhang, Weijuan Zhang
Summary: High infiltration of Foxp3(+)ROR gamma t(+) T cells predicts poor overall survival and therapeutic response in gastric cancer. These cells are associated with impaired effective function of CD8(+) T cells and can more precisely predict survival outcomes and chemotherapeutic responsiveness. The novel co-evaluation system might be useful for prognosis prediction and appropriate treatment in gastric cancer.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
